Perioperative Bridging for Mechanical Valve Replacement

Pre‑Procedure Anticoagulation Management

• Warfarin should be discontinued 3–4 days before the procedure to allow the INR to fall below 1.5 for major surgery or below 2.0 for minor surgery (Class I recommendation)【@3】.
• When the INR drops below 2.0 (typically 36–48 h pre‑procedure), initiate therapeutic‑dose subcutaneous LMWH (100 U/kg every 12 h) or enoxaparin 1 mg/kg every 12 h (preferred for outpatient bridging)【@3】.
• All patients with mechanical mitral valves require bridging anticoagulation; this is a Class I indication with no low‑risk exceptions【@3】.
• If LMWH is used, the last dose must be held 24 h before the procedure to ensure adequate drug clearance and minimize bleeding risk【@1】.
• If intravenous unfractionated heparin (UFH) is chosen, stop the infusion 4–6 h before the procedure (bolus 80 U/kg followed by 18 U/kg/h, target aPTT 60–80 s)【@3】.

Post‑Procedure Anticoagulation Resumption

• Restart warfarin at the patient’s usual maintenance dose on the evening of the procedure (12–24 h post‑op) once satisfactory hemostasis is confirmed【@3】.
• Resume therapeutic‑dose LMWH 12–24 h after the procedure if hemostasis is secure and bleeding risk is acceptable【@1】.
• Continue both warfarin and LMWH together until the INR reaches the therapeutic range (2.5–3.5 for mechanical mitral valves) on two consecutive measurements taken at least 24 h apart【@3】.
• Maintain LMWH for at least 24 h after the INR becomes therapeutic to provide overlap while warfarin’s full effect (new clotting factor synthesis) is achieved【@1】.

Target INR Values

• Mechanical mitral valves: target INR 2.5–3.5 (higher thrombotic risk than aortic positions)【@3】.
• Bileaflet mechanical aortic valves without additional risk factors: target INR 2.0–3.0【@3】.

Indications and Exceptions

• Mechanical mitral valves carry markedly higher thrombotic risk; valve thrombosis can develop within days of sub‑therapeutic anticoagulation (supporting the need for bridging)【@3】.
• 2024 AHA/ACC guidelines state that mechanical mitral valves remain the sole absolute indication for routine bridging, despite broader questioning of bridging in other scenarios【@6】 (Level C evidence, Class I).
• Patients with bileaflet mechanical aortic valves and no additional risk factors (no atrial fibrillation, no prior thromboembolism, normal LV function, age < 65) may safely interrupt warfarin without bridging【@3】.

Vitamin K Management

• High‑dose vitamin K (>2.5 mg) should not be used routinely for pre‑operative INR reversal because it can cause prolonged warfarin resistance and increase thrombotic risk in mechanical valve patients【@3】.
• For emergency reversal, administer fresh‑frozen plasma or 4‑factor prothrombin complex concentrate together with low‑dose oral vitamin K (1–2 mg)【@3】.

Peri‑operative Monitoring

• Obtain an INR 1–2 days before the procedure to verify that it has fallen below the required threshold (<1.5 for major surgery)【@1】.
• After restarting warfarin, check the INR daily beginning 24–48 h post‑procedure until two consecutive therapeutic values are achieved【@1】.
• If UFH is used, monitor aPTT with a target range of 60–80 seconds【@3】.

Evidence Quality

• Bridging recommendations are primarily based on observational cohort studies (Level C evidence); randomized trials in mechanical valve patients are lacking. Nevertheless, the consistent finding of high thrombotic risk without bridging in mechanical mitral valves supports a Class I recommendation【@6】.

Post‑operative Anticoagulation Management for Patients with Mechanical Aortic Valves

Warfarin Re‑initiation

• Restart oral warfarin at the patient’s usual maintenance dose within 12–24 hours after surgery once satisfactory hemostasis is confirmed. American College of Cardiology recommendation. 1

Warfarin Pharmacodynamics

• Full anticoagulant effect of warfarin requires 48–72 hours for adequate depletion of vitamin‑K‑dependent clotting factors after therapy begins. This underlies the need for an overlap period with parenteral anticoagulation. American Heart Association evidence. [2][3]

Vitamin K Administration

• High‑dose vitamin K (> 2.5 mg) should be avoided because it can produce prolonged warfarin resistance and increase the risk of thrombo‑embolism. American Heart Association guidance. 2

Thrombotic Risk in Low‑Risk Mechanical Aortic Valves

• Patients with bileaflet mechanical aortic valves without additional risk factors (e.g., atrial fibrillation, prior thrombo‑embolism, left‑ventricular dysfunction) have a relatively low baseline thrombotic risk. American Heart Association data. [2][3]

Bridging (Enoxaparin Overlap) Protocol

• After initiating enoxaparin bridging, the protocol requires maintaining enoxaparin until two consecutive therapeutic INR measurements are obtained at least 24 hours apart, ensuring adequate overlap while warfarin reaches full effect. American College of Cardiology protocol. 1